[Monoclonal antibody-based design of antitumor drugs: prerequisites and progress]

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Monoclonal antibodies (MAbs) targeting tumor-specific antigens represent a promising strategy for developing selective antitumor drugs.
• Thousands of MAbs have been generated, with many showing efficacy in preclinical and clinical studies, and several approved for oncological care.
• The N. N. Blokhin Russian Cancer Research Center (RCRC) has established MAb production technology.

Purpose of the Study:

• To highlight the development and application of monoclonal antibody technology at RCRC.
• To introduce novel MAb-based drug candidates, Imyteran and ATEMA, for therapeutic use.
• To underscore the potential for developing cost-effective MAb alternatives.

Main Methods:

• Development and application of monoclonal antibody production technology.
• Preclinical design and development of MAb-based therapeutic agents.
• Clinical trials for novel drug candidates.

Main Results:

• Successful implementation of MAb production technology at RCRC.
• Development of Imyteran and ATEMA, MAb-based drugs currently undergoing clinical trials.
• Preclinical design of a diverse range of MAbs with potential to replace imported alternatives.

Conclusions:

• Monoclonal antibody technology is successfully applied at RCRC for developing targeted therapies.
• Novel MAb-based drugs, Imyteran and ATEMA, show therapeutic potential and are under clinical investigation.
• RCRC is actively developing a portfolio of MAbs for potential clinical use and to reduce reliance on imported drugs.